Definitive Healthcare Corp. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The company provides healthcare commercial intelligence through a SaaS platform; substantially all revenue comes from subscriptions. Comparisons below are to Q1 2023, whose financial statements were previously restated.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $63.5 million | $59.2 million |
| Gross profit / GAAP gross margin | $50.4 million / 79% | $47.3 million / 80% |
| Operating loss | $16.2 million | $12.3 million |
| Net loss | $12.7 million | $16.0 million |
| Net loss attributable to Definitive Healthcare Corp. / diluted loss per share | $9.5 million / $0.08 | $12.1 million / $0.11 |
| Operating cash flow | $16.6 million | $15.0 million |
| Adjusted EBITDA (non-GAAP) / margin | $20.0 million / 32% | $15.7 million / 26% |
Revenue grew 7% year over year: subscription revenue rose $3.2 million to $61.8 million, and professional services revenue rose $1.0 million to $1.7 million. GAAP gross margin declined one percentage point; adjusted gross margin was 84% in both periods. Operating expenses increased 12% to $66.6 million, including higher restructuring costs and equity compensation. The operating loss widened despite improved net loss, helped by a $2.3 million tax receivable agreement (TRA) remeasurement gain versus a $3.6 million loss a year earlier, and higher interest income.
Cash and cash equivalents were $106.0 million and short-term investments $189.2 million at quarter-end, totaling $295.2 million. The company also reported $74.4 million available under its revolving facility. Operating cash flow was positive, but cash and equivalents declined $25.0 million from year-end, reflecting investing and financing outflows. Investing cash use was $24.0 million, including $13.5 million for Carevoyance net of cash acquired; financing cash use was $17.2 million, including $7.0 million of TRA payments and $3.4 million of term-loan repayments.
Term-loan principal was $254.4 million ($253.0 million net of issuance costs), with a 7.18% effective rate and September 2026 maturity; no revolver balance was outstanding. The facility is secured, includes financial covenants, and the company reported covenant compliance. A balloon payment of approximately $220 million is due at maturity. Deferred revenue was $108.1 million, and remaining performance obligations were $270.3 million.
Material changes and business developments
- Customer count was approximately 2,800, down from approximately 3,000 a year earlier; Enterprise Customers rose to 559 from 529. Management cited disproportionate churn among smaller customers.
- The company acquired Carevoyance on January 16, 2024, for $13.7 million in cash. Its post-acquisition revenue and loss were not material. The acquisition added $7.1 million of goodwill and $7.0 million of identifiable intangible assets on a provisional basis.
- A restructuring plan announced in January provides for a workforce reduction of approximately 150 people. Q1 restructuring charges were $7.2 million; $2.0 million remained accrued at quarter-end. The company expected a further $0.5 million of charges in Q2 and substantial completion by the end of Q2.
- Q1 equity-based compensation was $15.6 million versus $11.1 million, including approximately $6.9 million from accelerated vesting tied to the restructuring and an executive departure.
Outlook, risks, and unusual items
- Management expects Q2 and full-year 2024 revenue growth to be slower than in the corresponding 2023 periods. Restructuring-related go-to-market changes disrupted Q1 sales, particularly new business, upsells, and professional services; management expected disruption to continue into Q2. Subscription renewals were in line with expectations.
- Management expects 2024 revenue growth to be affected by longer sales cycles, deferred purchasing decisions, heightened churn, and cancellations, particularly among smaller customers and in life sciences and provider markets. It also expects modestly lower gross margin due to expanded data sources and acquisition-related costs. No numerical revenue or earnings guidance is provided in the supplied filing text.
- The company reported a material weakness in controls over sales-tax collection, remittance, and recording; disclosure controls were therefore deemed ineffective as of March 31, 2024. Remediation efforts are underway, but the weakness was not yet remediated.
- The company recorded a valuation allowance against deferred tax assets it concluded were not more likely than not to be realized. The TRA liability was $138.3 million; the company generally owes TRA parties 85% of realized qualifying tax benefits. Tax-basis adjustments and payments are subject to uncertainty, including possible IRS challenge.
- Interest-rate exposure remains relevant: the term loan bears a variable rate, partially hedged by swaps. The company estimated that, excluding swaps, a 1 percentage-point rate change would affect quarterly interest expense by approximately $0.6 million. It expects to recognize about $3.7 million of hedge gains as reduced interest expense over the next 12 months.
- Populi contingent consideration had a $9.0 million fair value at quarter-end, based on revenue targets for 2024 and 2025, with potential earn-out payments ranging from zero to $28.0 million. The Carevoyance purchase-price allocation remains provisional.
- After quarter-end, the board authorized a stock repurchase program of up to $20.0 million through December 31, 2024; no repurchases had been made as of May 7, 2024. The filing also reports a May 2024 change in executive roles.
- Management says liquidity is sufficient for at least the next 12 months, while noting uncertainty from macroeconomic conditions and possible constraints on future financing. The filing reports no material changes to risk factors since the 2023 Form 10-K and says ordinary-course legal matters are not expected to have a material adverse effect.
Key facts for investors to verify
- Whether churn, sales-cycle length, and go-to-market disruption improve, and how customer count, Enterprise Customers, and NDR evolve; the filing does not provide a current NDR figure.
- Whether restructuring delivers expected cost and margin benefits, including the remaining charges and effects of accelerated stock compensation.
- Whether reported Adjusted EBITDA growth translates into sustained GAAP improvement; assess the substantial exclusions, including equity compensation and transaction, integration, and restructuring costs.
- Progress in remediating the sales-tax control weakness and any resulting tax liabilities or restatements.
- Term-loan repayment and refinancing plans ahead of the 2026 maturity, interest-rate exposure, TRA payments, and the funding impact of any share repurchases.
- Final Carevoyance purchase accounting and performance, and the assumptions supporting Populi earn-out fair value and potential payments.